A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA (Belimumab)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary) ; Antimalarials; Corticosteroids; Immunosuppressants
Indications Systemic lupus erythematosus
Focus Adverse reactions
Acronyms SABLE
Sponsors GSK; Human Genome Sciences

Most Recent Events

02 Jun 2021 Planned End Date changed from 16 Jan 2025 to 17 Feb 2025.
02 Jun 2021 Planned primary completion date changed from 16 Jan 2025 to 17 Feb 2025.
28 Feb 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight